编者按：2022年欧洲肿瘤内科学会年会（ESMO 2022）将于当地时间9月9～13日在法国巴黎以线上、线下相结合的形式举行。日前，官网已经发布所有专场的讲课题目，本届ESMO大会上，多项重磅研究结果将会公布。《肿瘤瞭望》特进行整理，以飨读者。
9月9日Proffered Paper session: Breast cancer， metastatic
LBA15-MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+， HER2- advanced breast cancer (ABC)
MONARCH 3研究中期总生存期（OS）结果：阿贝西利联合非甾体芳香化酶抑制剂（NSAI）治疗HR+/HER2-晚期乳腺癌（ABC）
讲者：Matthew P. Goetz (Rochester， United States of America)
报告时间：16:00 - 16:10
LBA16-Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial
一项Ⅲ期试验：达尔西利联合来曲唑或阿那曲唑用于HR+/HER2-晚期乳腺癌（DAWNA-2）患者的一线治疗
讲者：徐兵河 院士（中国医学科学院肿瘤医院）
报告时间：16:10 - 16:20
LBA76 - Overall survival (OS) results from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
Ⅲ期TROPiCS-02研究的总生存期（OS）结果：sacituzumab govitecan（SG）对比医生选择的治疗方案（TPC）用于HR+/HER2-晚期乳腺癌患者的治疗
讲者：Hope S. Rugo (San Francisco， United States of America)
报告时间：16:20 - 16:30
210O - Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
突变特征分析揭示了在ER+/HER2-转移性乳腺癌（MBC）患者中，与内分泌治疗（ET）+/- CDK4/6抑制耐药相关的基因组不稳定模式。
讲者：Antonio Marra (New York， United States of America)
报告时间：16:20 - 16:30
LBA17-Primary endpoint results of SYNERGY， a randomized phase 2 trial， first-line chemo-immunotherapy trial of durvalumab， paclitaxel， and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
随机Ⅱ期SYNERGY试验：度伐利尤单抗、紫杉醇和卡铂联合或不联合抗CD73抗体oleclumab用于晚期或转移性三阴性乳腺癌（TNBC）患者的一线化学免疫治疗主要终点结果
讲者：Laurence Buisseret (Brussels， Belgium)
报告时间：17:00 - 17:10
9月10日Proffered Paper session: Breast cancer， early stage
133O - Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy: final results of the phase 3 DATA trial
DATA Ⅲ期试的验最终结果：内分泌辅助治疗后延长芳香化酶抑制治疗。
讲者：Vivianne C. Tjan-Heijnen (Maastricht， Netherlands)
报告时间：10:15 - 10:25
LBA13 - Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial
BELLINI试验的初步结果：纳武利尤单抗联合伊匹木单抗治疗具有肿瘤浸润淋巴细胞（TIL）的早期三阴性乳腺癌（TNBC）
讲者：Iris Nederlof (Amsterdam， Netherlands)
报告时间：10:25 - 10:35
LBA14 - Impact of age， Recurrence Score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials
ADAPT和ADAPTcycle研究分析：年龄、复发评分（RS）和卵巢功能抑制（OFS）对术前短期内分泌治疗效果的影响
讲者：Oleg Gluz (M?nchengladbach， Germany)
报告时间：11:00 - 11:10
134O-Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: end-of-study results from a randomised， phase 3 trial of the Gruppo Italiano Mammella (GIM).
早期乳腺癌患者的剂量密集辅助化疗：随机Ⅲ期Gruppo Italiano Mammella（GIM）研究的最终结果
讲者：Lucia Del Mastro (Genova， Italy)
报告时间：11:10 - 11:20
9月10日Mini Oral session: Breast cancer， metastatic
LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+， HER2+ advanced breast cancer (monarcHER): a randomized， open-label， phase 2 trial
abemaciclib +曲妥珠单抗+/- fulvestrant对比曲妥珠单抗+化疗在HR+/HER2+晚期乳腺癌患者中的最终总生存结果（monarcHER研究）：一项随机、开放标签的Ⅱ期临床试验
讲者：Fabrice André (Villejuif， France)
报告时间：14:45-14:50
LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase 3 trial
吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌（PHILA）：一项随机Ⅲ期试验
讲者：徐兵河院士（中国医学科学院肿瘤医院）
报告时间：14:50 - 14:55
LBA20 - Open-label， randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC)， an estrogen receptor 1 (ESR1) mutation， and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
一项开放标签的随机研究，对比lasofoxifene （LAS）和fulvestrant（Fulv）在经AI联合CDK4/6抑制剂治疗后疾病进展，存在ESR1突变的局部进展/转移性ER+/HER2-乳腺癌的治疗效果
讲者：Matthew P. Goetz (Rochester， United States of America)
报告时间：15:05 - 15:10
211MO - Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+， HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2， randomised， open-label acelERA BC study
Ⅱ期、随机、开放标签的acelERA BC研究初步分析：比较Giredestrant（GDC-9545）与医生选择的内分泌单药治疗（PCET）在ER+/HER2-局部晚期/转移性乳腺癌（LA/mBC）患者中的治疗效果
讲者：Miguel Martin Jimenez (Madrid， Spain)
报告时间：15:10 - 15:15
212MO - AMEERA-3， a Phase 2 study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2? advanced breast cancer (aBC)
AMEERA-3研究：一项Ⅱ期研究，在内分泌耐药的ER+/HER2-晚期乳腺癌（aBC）患者中对比amcenestrant（AMC）与医师选择的内分泌治疗（TPC）的疗效
讲者：Sara M. Tolaney (Boston， United States of America)
报告时间：15:15 - 15:20
213MO - Primary endpoint analysis of a randomized phase 2 of darolutamide or capecitabine in patients with triple-negative androgen receptor positive advanced breast cancer (UCBG3-06 START trial)
Ⅱ期UCBG3-06 START试验主要终点分析：darolutamide或卡培他滨治疗三阴性雄激素受体阳性晚期乳腺癌
讲者：Monica Arnedos (Bordeaux， France)
报告时间：15:35 - 15:40
214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase 3 TROPiCS-02 study
在TROPiCS-02期研究中，通过HER2免疫组化（IHC）检测HER2状态，评估Sacituzumab govitecan（SG）对激素受体阳性/人表皮生长因子受体2阴性（HR+/HER2-）转移性乳腺癌（MBC）的治疗疗效
讲者：Frederik Marmé (Mannheim， Germany)
报告时间：15:40 - 15:45
215MO - ICON–a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor positive breast cancer
ICON：一项随机Ⅱb期研究，评估化疗联合伊匹木单抗和纳武利尤单抗治疗转移性激素受体阳性乳腺癌
讲者：Jon Amund Kyte (Oslo， Norway)
报告时间：15:45 - 15:50
216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): the METEORA-II trial (IBCSG 54-16)
METEORA-II试验（IBCSG 54-16）：一项随机Ⅱ期试验，节律性口服长春瑞滨+环磷酰胺+卡培他滨（VEX）对比周疗紫杉醇（P）作为ER+/HER2-转移性乳腺癌患者（MBC）的一线或二线治疗的疗效
讲者：Elisabetta Munzone (Milan， Italy)
报告时间：15:50 - 15:55
9月11日Mini Oral session: Basic science & translational research
LBA72-Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial
DAISY试验患者的生物标志物分析：阐明Trastuzumab deruxtecan（T-DXd）的作用机制和耐药性
讲者：Maria Fernanda Mosele (Villejuif， France)
报告时间：14:45 - 14:50
9月12日Mini Oral session: Breast cancer， early stage
135MO - HRQoL With Neoadjuvant Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy， Followed by Adjuvant Pembrolizumab vs Placebo for Early-Stage TNBC: Results From KEYNOTE-522
KEYNOTE-522的HRQoL结果：新辅助帕博利珠单抗+化疗vs安慰剂+化疗，序贯辅助帕博利珠单抗 vs 安慰剂治疗早期TNBC
讲者：Rebecca A. Dent (Singapore， Singapore)
报告时间：08:30 - 08:35
136MO - Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study
在IBCSG 22-00研究中，TNBC亚型中低剂量环磷酰胺和甲氨蝶呤维持化疗的效果差异
讲者：Andrea Joaquin Garcia (Brussels， Belgium)
报告时间：08:35 - 08:40
137MO - Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer
术前局部麻醉对早期乳腺癌肿瘤周围浸润的影响
讲者：Rajendra Badwe (Mumbai， India)
报告时间：08:40 - 08:45
139MO - Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
ALTTO试验中，确定与辅助曲妥珠单抗治疗预后相关的生物驱动的HER2阳性乳腺癌亚组
讲者：Mattia Rediti (Brussels， Belgium)
报告时间：09:00 - 09:05
140MO - HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
PerELISA试验的相关分析：接受曲妥珠单抗（T）和帕妥珠单抗（P）新辅助治疗的HER2阳性/激素受体阳性（HR+/HER2+）乳腺癌（BC）患者HER2DX基因组检测
讲者：Valentina Guarneri (Padova， Italy)
报告时间：09:05 - 09:10
138MO - Prognostic performance of Breast Cancer Index (BCI) in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial
TEAM试验中乳腺癌指数（BCI）对绝经后早期HR+乳腺癌患者的预后预测效果
讲者：John M. Bartlett (Edinburgh， United Kingdom)
报告时间：09:25 - 09:30
141MO - Pathological response and early survival data according to TNBCtype4 classifier in operable triple negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel
新辅助接受卡铂+多西他赛治疗的可手术三阴性乳腺癌，根据TNBCtype4分类的病理缓解和早期生存数据
讲者：Isabel Echavarria Diaz-Guardamino (Madrid， Spain)
报告时间：09:30 - 09:35
京公网安备 11010502033352号